↓ Skip to main content

Multicenter Phase II Study of Tivozanib (AV‐951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

Overview of attention for article published in Oncologist, April 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
1 X user
patent
2 patents
f1000
1 research highlight platform

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Multicenter Phase II Study of Tivozanib (AV‐951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer
Published in
Oncologist, April 2014
DOI 10.1634/theoncologist.2012-0378
Pubmed ID
Authors

Brian M. Wolpin, Kimmie Ng, Andrew X. Zhu, Thomas Abrams, Peter C. Enzinger, Nadine J. McCleary, Deborah Schrag, Eunice L. Kwak, Jill N. Allen, Pankaj Bhargava, Jennifer A. Chan, Wolfram Goessling, Lawrence S. Blaszkowsky, Jeffrey G. Supko, Meaghan Elliot, Kaori Sato, Eileen Regan, Jeffrey A. Meyerhardt, Charles S. Fuchs

Abstract

Treatments that target the vascular endothelial growth factor (VEGF) pathway have efficacy in colorectal cancer. We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor).

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 3%
Unknown 31 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 25%
Student > Master 6 19%
Other 4 13%
Student > Doctoral Student 3 9%
Student > Bachelor 2 6%
Other 7 22%
Unknown 2 6%
Readers by discipline Count As %
Medicine and Dentistry 14 44%
Biochemistry, Genetics and Molecular Biology 5 16%
Nursing and Health Professions 4 13%
Agricultural and Biological Sciences 2 6%
Unspecified 1 3%
Other 2 6%
Unknown 4 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2022.
All research outputs
#4,760,513
of 25,374,917 outputs
Outputs from Oncologist
#1,181
of 3,982 outputs
Outputs of similar age
#44,177
of 239,867 outputs
Outputs of similar age from Oncologist
#16
of 48 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,982 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,867 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.